Physician profile
Anthony Wayne Miller
NPI 1417922568
$1,445.85
in general payments reported to CMS, 2019-2025
20 companies · $72.47 in 2025
The $72.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $152 · 2021: $267 · 2022: $86.42 · 2023: $325 · 2024: $245 · 2025: $72.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $235.50 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $188.12 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $178.99 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $145.23 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $136.37 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Melinta Therapeutics, LLC | $71.92 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $63.40 | 2023-2024 | Soliris, Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $58.21 | 2019-2025 | Eliquis |
| Mentor Worldwide LLC | $53.72 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.88 | 2023 | Gattex |
| Boston Scientific Corporation | $41.09 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.83 | 2019-2023 | Jardiance |
| Neurelis, INC. | $37.41 | 2024 | Valtoco |
| Novo Nordisk INC | $37.22 | 2019 | |
| Abbvie INC. | $33.38 | 2021-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.01 | 2021 | |
| Vyera Pharmaceuticals, LLC | $17.88 | 2019 | |
| Madrigal Pharmaceuticals | $17.12 | 2024 | Resmetirom |
| Gilead Sciences, INC. | $12.76 | 2023 | Veklury |
| Allergan, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.